An experimental Ebola drug healed all 18 monkeys infected with the deadly virus in a study, boosting hopes that the treatment might help fight the outbreak raging through west Africa — once more of it can be made.
The monkeys were given the drug, ZMapp, three to five days after they were infected with the virus and when most were showing symptoms. That is several days later than any other experimental Ebola treatment tested so far.
The drug also completely protected six other monkeys given a slightly different version of it three days after infection in a pilot test. These two studies are the first monkey tests ever done on ZMapp.
“The level of improvement was utterly beyond my honest expectation,” said one study leader, Gary Kobinger of the Public Health Agency of Canada in Winnipeg.
“For animal data, it’s extremely impressive,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which had a role in the work.
It is not known how well the drug would work in people, who can take up to 21 days to show symptoms and are not infected the way the lab monkeys were.
Several experts said it is not possible to estimate a window of opportunity for treating people, but that it was encouraging that the animals recovered when treated even after advanced disease developed.
The study was published online on Friday by the journal Nature.
ZMapp had never been tested in humans before two US aid workers who got Ebola while working in Africa were allowed to try it. The rest of the limited supply was given to five others.
There is no more ZMapp now, and once a new batch is ready, it still needs some basic tests before it can be tried again during the African outbreak, Fauci said.
“We do need to know what the proper dose is” in people and that it is safe, he said.
ZMapp is three antibodies that attach to cells infected with Ebola, helping the immune system kill them.
Of the seven people known to have been treated with ZMapp, two have died — a Liberian doctor and a Spanish priest. The priest received only one of three planned doses. The two Americans recovered, as have two Africans who received ZMapp in Liberia — a Congolese doctor and a Liberian physician’s assistant, who were to be released from a treatment center yesterday.
Doctors have said there is no way to know whether ZMapp made a difference or the survivors recovered on their own, as about 45 percent of people infected in this outbreak have.
ZMapp’s maker, Mapp Biopharmaceutical Inc, of San Diego, California, has said the small supply of the drug is now exhausted and that it will take several months to make more. The drug is grown in tobacco plants and was developed with US government support.
Kobinger said it takes about a month to make 20 to 40 doses at a Kentucky plant where the drug is being produced. Officials have said they are looking at other facilities and other ways to ramp up production, and Kobinger said there were plans for a clinical trial to test ZMapp in people early next year.
The monkey study involved scientists from the Canada health agency, Mapp Biopharmaceutical, the US National Institutes of Health and the US Army Medical Research Institute of Infectious Disease.
Eighteen monkeys were given lethal amounts of Ebola in a shot, then received three intravenous doses of ZMapp, given three days apart starting three to five days after they were infected.
All treated with ZMapp survived; three other infected monkeys who did not get the drug died within eight days.
Primates have been good stand-ins for people for many viral diseases, but how well they predict human responses to Ebola, “we just don’t know,” Duke University infectious disease specialist Cameron Wolfe said.
The study also “tells us nothing about side effects” people might have, he added.
Still, it was encouraging that even monkeys with severe symptoms got better, said Wolfe and Erica Ollmann Saphire, a Scripps Research Institute professor who has worked with some of the study leaders on antibodies to Ebola.
“The treatment window in humans needs to be established in a well-controlled trial” that also would explore the correct dose of ZMapp in people, Saphire said. “Given its tremendous efficacy in the ... primates, I don’t see how it couldn’t be helpful in people.”
FRENCH AID: Paris has sent a navy ship and aircraft from Reunion Island with some pollution control equipment, but rough seas are spreading the oil spill The operator of a Japanese bulk carrier which ran aground off Mauritius in the Indian Ocean yesterday apologized for a major oil spill, which officials and environmentalists say is creating an ecological disaster, as police prepared to board the ship. The MV Wakashio, operated by Mitsui OSK Lines, struck the reef on Mauritius’ southeast coast on July 25. “We apologize profusely and deeply for the great trouble we have caused,” Mitsui OSK Lines executive vice president Akihiko Ono said at a news conference in Tokyo. The company would “do everything in their power to resolve the issue,” he said. At least 1,000 tonnes of
Three Micronesian sailors stranded on a remote Pacific island have been found alive and well after a rescue team spotted their giant SOS message written into the sand on a beach. Australian and US military aircraft found the three men on tiny Pikelot island, nearly 200km west of where they had set off. Rescuers said that the men were “in good condition” with no significant injuries. The men had been missing for three days after their 7m skiff ran out of fuel and strayed off course. Authorities in the US territory of Guam raised the alarm on Saturday after the men failed to complete
A cat that went missing on a family holiday on the shores of Loch Lomond, Scotland, has been identified 12 years later. Tortoiseshell-and-white Georgie spent October half term in 2008 with her owners at the Rowardennan campsite, but vanished as they were due to return home to Greater Manchester, England. After a search of the site the Davies family departed without Georgie, hoping the three-year-old microchipped feline would be located by someone. Over the intervening 12 years, she remained close to the Queen Elizabeth Forest Park site, being fed and cared for by campsite staff and holidaymakers. After the COVID-19 pandemic hit and lockdown
LIFELONG LOSS: Jiro Hamasumi, who was not quite born when an atomic bomb hit Hiroshima, lost his father and other relatives, but said he thinks about his father daily As Japan marks 75 years since the devastating attacks on Hiroshima and Nagasaki, the last generation of nuclear bomb survivors is working to ensure their message lives on after them. The “hibakusha” — literally “person affected by the bomb” — have for decades been a powerful voice calling for the abolition of nuclear weapons. There are an estimated 136,700 left, many of whom were infants or soon to be born at the time of the attacks. The average age of a survivor now is a little over 83, according to the Japanese Ministry of Health, lending an urgency as they share their testimonies